General
Preferred name
VORTIOXETINE
Synonyms
VORTIOXETINE HYDROBROMIDE ()
Vortioxetine (Lu AA21004) HBr ()
Vortioxetine HBr ()
Lu AA21004 hydrobromide ()
Lu AA 21004 ()
Vortioxetine (hydrobromide) ()
Lu AA21004 (hydrobromide) ()
LU AA 21004 HYDROBROMIDE ()
Trintellix ()
Lu AA21004 (HBr) ()
Brintellix ()
LU-AA21004 HBR ()
Lu-aa21004 hydrobromide ()
Lu aa21004 hbr ()
LU-AA21004 ()
LU AA21004 ()
Vortioxetina ()
LUAA21004 ()
SF001 ()
SF-001 ()
Vortioxetine bromide ()
VORTIOXETINE HEMIHYDROBROMIDE ()
Vortioxetine-d8 ()
P&D ID
PD012584
CAS
960203-27-4
508233-74-7
2140316-62-5
Tags
available
drug
drug candidate
Approved by
PMDA
EMA
FDA
First approval
2013
Drug indication
Attention deficit hyperactivity disorder
Anxiety disorder
Major depressive disorder
Mood disorder
Drug Status
approved
investigational
Max Phase
4.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Vortioxetine (Lu AA 21004) hydrobromide is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of 5-hydroxytryptamine transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial 5-HT1B agonist (Ki: 15 nM, 33 nM)[1][2].
DESCRIPTION
Vortioxetine is an atypical (multimodal) antidepressant .
(GtoPdb)
DESCRIPTION
Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial agonist of 5-HT1B (Ki: 15 nM, 33 nM)[1][2].
PRICE
35
DESCRIPTION
Vortioxetine hydrobromide (Lu AA21004 hydrobromide) is a serotonin (5-HT) modulator and stimulator (SMS), inhibits 5-HT1A/1B/3A/7 receptor and SERT (IC50: 15/33/3.7/19/1.6 nM).
(TargetMol Bioactive Compound Library)
DESCRIPTION
Vortioxetine (Lu AA 21004) is a serotonergic antidepressant used for major depression disorders. Vortioxetine has been associated with a low rate of minor serum aminotransferase elevations during treatment.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
24
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
NCATS Inxight Approved Drugs
Other bioactive compounds
ReFrame library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
223
Molecular Weight
298.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
3.86
TPSA
15.27
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.93
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT1A
5-HT1B
5-HT3A
5-HT7
Serotonin Transporter
SERT
HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4
MOA
serotonin receptor agonist, serotonin receptor antagonist
Indication
depression
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data

